1. “Whether the district court legally erred in its framework for evaluating objective indicia of non-obviousness, by (a) concluding that the claims were obvious before even analyzing the compelling objective...
“Whether the district court erred in holding that any reasonable juror was required to find that Sanofi-Regeneron established non-enablement by clear-and- convincing evidence.”
1. “Whether the asserted claims are invalid because: (1) They were anticipated by the prior art; or (2)They are not enabled and lack sufficient written description.”
2. “Whether the asserted claims...
1. “Whether, in determining that Patent No. 6,477,151 (the ‘151′, or the ‘’151 Patent’) is unenforceable, the district court committed an error of law in failing to apply a ‘but...
“Whether substantial evidence supports the jury’s verdict that Teva willfully induced infringement of GSK’s patented method of treating congestive heart failure where: (a) Teva encouraged the infringing use in promotional...
1. “Did the district court err in excluding evidence of comparable-license negotiations under the parol-evidence rule in a Georgia-Pacific analysis and the resulting royalty opinions?”
2. “Did the district court err...
1. “Did the CAVC misinterpret Rule 23(a)’s commonality requirement to require that a proposed class of disabled veterans seeking class certification of claims alleging unreasonable system-wide delay always identify a...
“I. Network-1’s Appeal
A. Independent Basis for Verdict: Does the evidence compel a finding of non-infringement irrespective of the challenged constructions?
B. Claim Construction:
1. Did the district court properly construe ‘low level...
1. “Whether contractual language providing that patents ‘shall be the property of [an employing entity, here, the University of Michigan],’ without requiring any further acts from the parties, operates as...
1. “Whether the insurers’ statutory claims fail because Congress did not intend for insurers to receive damages as compensation for cost-sharing payments that Congress declined to fund.”
2. “Whether the insurers’...
1. “Did the district court err in concluding that it cannot exercise personal jurisdiction over PerDiemCo even though (a) PerDiemCo expressly and repeatedly accused Trimble, a company based in northern...
1. “Whether the Court should vacate the district court’s judgment of noninfringement by Watson and direct entry of the consent judgment necessary to effectuate the parties’ agreement to settle, because:...
“Congress has conferred limited authority on the judiciary to charge fees for access to electronic court records. These fees may be imposed ‘as a charge for services rendered’ to ‘reimburse...
1. “Is Bio-Rad barred as a matter of law from asserting infringement under the doctrine of equivalents where it amended its claims to exclude the very terrain it now accuses,...
1. “Section 1.2(d) of the License Agreement at issue in this case permits Alkem to launch its generic Colcrys® product a specified time period ‘after the date of a Final...
1. “Section 1.2(d) of the License Agreement at issue in this case permits Mylan to launch its generic colchicine product a specified time period ‘after the date of a Final...
“The primary issue on appeal is whether the Board erred in denying, based only on a § 101 patent eligibility challenge, Uniloc’s motion to amend the patent in this inter...
1. “Whether the CFC erred in ruling that a number of deeds for the rail corridor at issue in this case conveyed merely an easement to the railroad where no...
“Whether a claimant’s general statement requesting benefits on a formal claim form that identifies specific disabilities constitutes a claim for all ‘reasonably identifiable’ diagnoses within the claimant’s records.”
1. “Whether Arthrex should be extended to ex parte examination cases.”
2. “Whether the Director’s purported ability to refuse to issue a patent if the Patent Trial and Appeal Board approves...
